ALK Fusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy

BACKGROUND. Genomic fusions of the anaplastic lymphoma kinase gene (ALK) are a well‐established therapy target in non‐small cell lung cancer (NSCLC). From a survey of 114,200 clinical cases, we determined the prevalence of ALK rearrangements (rALK) in non‐NSCLC tumors and report their responsiveness...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Ross, Jeffrey S., Ali, Siraj M., Fasan, Omotayo, Block, Jared, Pal, Sumanta, Elvin, Julia A., Schrock, Alexa B., Suh, James, Nozad, Sahar, Kim, Sungeun, Jeong Lee, Hwa, Sheehan, Christine E., Jones, David M., Vergilio, Jo‐Anne, Ramkissoon, Shakti, Severson, Eric, Daniel, Sugganth, Fabrizio, David, Frampton, Garrett, Miller, Vince A., Stephens, Philip J., Gay, Laurie M.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Cancer Diagnostics and Molecular Pathology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728036/
https://ncbi.nlm.nih.gov/pubmed/29079636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados